Abstract
The pharmacokinetics of ciprofloxacin was studied in three groups of healthy volunteers comprising a total of 16 males and 16 females (age 21-35 years; body weight 52-80 kg). Single oral doses of 50, 100, 250, 500 and 750 mg were given to fasting subjects. The 250 mg dose was repeated after a breakfast. Intravenous doses of 50, 100 and 200 mg were given by short infusion in a randomized cross-over sequence. Concentrations of the drug in serum and urine were determined by high-performance liquid chromatography and by a microbiological assay. Mean peak concentrations between 0.37 +/- 0.49 mg/l (100 mg dose) and 1.97 +/- 0.50 (750 mg dose) were measured 60-75 min after oral administration. Twelve hours after 750 mg ciprofloxacin, serum concentrations were 0.15 +/- 0.05 mg/l. Taking a breakfast reduced absorption by 15-20% compared to the fasting state, as judged by peak concentrations, AUC and renal excretion. After 200 mg i.v. (20 min infusion period), initial serum concentrations of 4.0 +/- 1.2 mg/l were observed which declined 12 h later to 0.070 +/- 0.025 mg/l. Mean cumulated recovery of ciprofloxacin from urine over 24 h varied between 25.5% and 33.6% of oral doses and between 53.2% and 57.4% of intravenous doses. Two of the three metabolites seen in the chromatograms were identified as M1 and M3 (oxo-ciprofloxacin). Cumulated renal excretion after an oral 250 mg dose was 1.2 +/- 0.4% of M1 and 5.5 +/- 1.6% of M3.(ABSTRACT TRUNCATED AT 250 WORDS)
MeSH Terms
Administration, Oral
Adult
Anti-Infective Agents/administration & dosage,blood,metabolism,urine
Biological Availability
Biotransformation
Chromatography, High Pressure Liquid
Ciprofloxacin
Female
Humans
Infusions, Parenteral
Kinetics
Male
Quinolines/administration & dosage,blood,metabolism,urine
Chemicals
Anti-Infective Agents
Quinolines
Ciprofloxacin
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Borner K
Höffken G
Lode H
Koeppe P
Prinzing C
Glatzel P
Wiley R
Olschewski P
Sievers B
Reinitz D
References (25)
25 references, click to expand
-
Dose- and sex-independent disposition of ciprofloxacin.
Eur J Clin Microbiol. 1984 Aug;3(4):363-6
PMID: 6489328
-
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Antimicrob Agents Chemother. 1984 Mar;25(3):331-5
PMID: 6721464
-
A program for non-linear regression analysis to be used on desk-top computers.
Comput Programs Biomed. 1980 Dec;12(2-3):121-8
PMID: 7249588
-
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6
PMID: 6660852
-
The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.
J Clin Pharmacol. 1985 Mar;25(2):82-8
PMID: 3157705
-
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64
PMID: 6222695
-
Norfloxacin disposition after sequentially increasing oral doses.
Antimicrob Agents Chemother. 1983 Feb;23(2):284-8
PMID: 6220672
-
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26
PMID: 6232895
-
The in vitro and in vivo activity of ciprofloxacin.
Eur J Clin Microbiol. 1984 Aug;3(4):339-43
PMID: 6237902
-
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
Eur J Clin Microbiol. 1983 Apr;2(2):111-5
PMID: 6222896
-
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
JAMA. 1981 Oct 2;246(14):1575-8
PMID: 7277631
-
In vitro activity of ciprofloxacin against Bacteroides, Haemophilus influenzae and Branhamella catarrhalis.
Eur J Clin Microbiol. 1984 Aug;3(4):370-1
PMID: 6333337
-
Pharmacokinetics of intravenously administered ciprofloxacin.
Antimicrob Agents Chemother. 1984 Aug;26(2):208-10
PMID: 6486762
-
Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.
Eur J Clin Microbiol. 1984 Aug;3(4):355-9
PMID: 6489326
-
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
Antimicrob Agents Chemother. 1985 Mar;27(3):375-9
PMID: 3158275
-
A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
Eur J Clin Microbiol. 1984 Aug;3(4):328-32
PMID: 6237900
-
Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
Eur J Clin Microbiol. 1984 Aug;3(4):333-8
PMID: 6237901
-
Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.
Antimicrob Agents Chemother. 1985 Aug;28(2):311-4
PMID: 2939796
-
Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.
J Pharm Sci. 1970 Jan;59(1):53-5
PMID: 5411325
-
Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.
Eur J Clin Microbiol. 1984 Aug;3(4):351-4
PMID: 6489325
-
Drug therapy. Clinical Pharmacokinetics (first of two parts).
N Engl J Med. 1975 Oct 2;293(14):702-5
PMID: 1160938
-
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.
Antimicrob Agents Chemother. 1985 Mar;27(3):353-6
PMID: 3158274
-
Diffusion of ciprofloxacin into prostatic fluid.
Eur J Clin Microbiol. 1984 Aug;3(4):360-2
PMID: 6489327
-
Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.
Antimicrob Agents Chemother. 1984 Nov;26(5):757-61
PMID: 6517559
-
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.
Antimicrob Agents Chemother. 1985 Mar;27(3):350-2
PMID: 3158273